Printer Friendly

Human iPSC-Derived MSCs Circumvent Aging-Related Problems.

DUSSELDORF, Germany, April 10, 2019 --The use of primary mesenchymal stem cells (MSCs) is fraught with aging-related shortfalls such as limited expansion and early senescence.

Human induced pluripotent stem cells (iPSCs)-derived MSCs (iMSCs) have been shown to be a useful clinically relevant source of MSCs that circumvent these aging-associated drawbacks.

The importance of this concept is shown by the successful Phase 1 clinical trial for the treatment of GvHD by Cynata Therapeutics and the National Health Service (U.K.) ("An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease").

[Editor's Note: Results of the trial from Cohort A were presented in a poster at the American Society of Hematology (ASH) annual meeting in December 2018. A Phase 2 trial is planned for this year. The trial is independent of the work carried out by Spitzhorn et al., described below.]

A collaborative study coordinated by James Adjaye of the Institute for Stem Cell Research and Regenerative Medicine (Heinrich-Heine University) analyzed the acquisition of rejuvenation-associated hallmarks in iMSCs.

In the study, the researchers compared cellular features, transcriptomes and secretomes of iMSCs differentiated from embryonic stem cells (ESCs-H1) and iPSCs, emanating from MSCs isolated young and elderly individuals.

The generated iMSCs (irrespective of source) met the criteria set out for MSCs and dendrogram analyses confirmed that the transcriptomes of all iMSCs clustered together with the parental MSCs and distinct from pluripotent stem cells.

Irrespective of donor age and initial cell type, iMSCs acquired a rejuvenation-associated 50-gene comprising signature which is also expressed in pluripotent stem cells but not in the parental MSCs.

In terms of regenerative medicine, iMSCs acquired a secretome similar to that of primary MSCs, thus highlighting their ability to act via paracrine signaling.

The iMSC concept has enabled circumventing the drawbacks associated with the use of adult MSCs and thus provide a promising tool for use in various clinical settings in the future.

Citation: Lucas-Sebastian Spitzhorn et al., Human iPSC-derived MSCs (iMSCs) from aged individuals acquire a rejuvenation signature. Stem Cell Research & Therapy, 2019; 10 (1) DOI: 10.1186/s13287-019-1209-x


Contact: James Adjaye,

COPYRIGHT 2019 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Stem Cell Research News
Date:Apr 22, 2019
Previous Article:Boosting Muscle Stem Cells May Treat Muscular Dystrophy, Aging Muscles.
Next Article:Company's Compound Enhances Vascular Regeneration In Retinal Ischemia.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters